Clinical Trial Update: A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Amgen's ABP-206 versus Opdivo (nivolumab) in unresectable or metastatic melanoma. The trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ABP-206 (nivolumab biosimilar)
• OPDIVO (nivolumab)

Snippet

Sponsor: Amgen | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING